Empowered Funds LLC purchased a new position in Pediatrix Medical Group, Inc. (NYSE:MD – Free Report) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 500,118 shares of the company’s stock, valued at approximately $12,668,000.
Several other hedge funds have also recently bought and sold shares of the company. Burney Co. acquired a new position in shares of Pediatrix Medical Group in the first quarter worth about $1,129,000. Jennison Associates LLC acquired a new stake in shares of Pediatrix Medical Group during the 4th quarter valued at about $768,000. Renaissance Technologies LLC increased its stake in shares of Pediatrix Medical Group by 12.9% in the 1st quarter. Renaissance Technologies LLC now owns 1,532,300 shares of the company’s stock valued at $32,776,000 after purchasing an additional 174,600 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in Pediatrix Medical Group by 139.1% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 69,069 shares of the company’s stock worth $1,493,000 after purchasing an additional 40,176 shares during the period. Finally, Fifth Third Bancorp boosted its position in Pediatrix Medical Group by 7,643.2% during the first quarter. Fifth Third Bancorp now owns 62,333 shares of the company’s stock worth $1,333,000 after purchasing an additional 61,528 shares in the last quarter. 97.71% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
MD has been the topic of several research analyst reports. Weiss Ratings lowered Pediatrix Medical Group from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday. Truist Financial lifted their price target on shares of Pediatrix Medical Group from $23.00 to $28.00 and gave the company a “hold” rating in a research note on Tuesday, July 14th. UBS Group boosted their price target on shares of Pediatrix Medical Group from $25.00 to $28.00 and gave the stock a “neutral” rating in a report on Thursday, August 6th. Mizuho set a $24.00 price objective on shares of Pediatrix Medical Group in a report on Friday, May 8th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $25.00 target price on shares of Pediatrix Medical Group in a research report on Wednesday, August 5th. Seven analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $25.00.
Pediatrix Medical Group Trading Down 0.5%
Shares of MD stock opened at $26.66 on Friday. Pediatrix Medical Group, Inc. has a fifty-two week low of $15.69 and a fifty-two week high of $27.94. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.32 and a current ratio of 1.32. The stock’s fifty day moving average is $26.06 and its two-hundred day moving average is $23.18. The firm has a market capitalization of $2.17 billion, a P/E ratio of 12.76 and a beta of 0.66.
Pediatrix Medical Group (NYSE:MD – Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04. The business had revenue of $487.78 million during the quarter, compared to analyst estimates of $478.49 million. Pediatrix Medical Group had a net margin of 8.96% and a return on equity of 20.05%. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.53 earnings per share. Research analysts expect that Pediatrix Medical Group, Inc. will post 2.17 earnings per share for the current fiscal year.
About Pediatrix Medical Group
Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.
Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.
Featured Articles
- Five stocks we like better than Pediatrix Medical Group
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pediatrix Medical Group, Inc. (NYSE:MD – Free Report).
Receive News & Ratings for Pediatrix Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediatrix Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.
